However, when a CpG oligonucleotide 1018 ISS was combined with rituximab subcutaneously in a phase II clinical trial the response rate was similar to that reported for rituximab alone.29 Although infiltration of CD8+ T cells and macrophages into tumor was observed, these data suggest that systemic administration of TLR agonists may be beneficial for sustained antitumor responses. Here, CD8A is linked to neoplasm.